NCT Number: NCT06628076
A. baumannii is known as the most frequently isolated organism in intensive care units (ICUs), causing a variety of nosocomial infections, including pneumonia, urinary tract infections (UTIs), bacteremia as well as skin and soft tissue infections. These infections are usually associated with high mortality rates ranging between 26% among hospitalized patients and 43% among ICU patients.
Trial opening soon.
Get NotifiedUp to 90 year
All sexes
Observational
Sohag, 534568, Egypt
Mohammed Ahmed Mahmoud, lecturer
CONTACT
Mona Fatooh mohmad, professor
CONTACT
Noha Saber Shafik, lecturer
CONTACT
Shimaa Anwar Ahmed, lecturer
CONTACT
sohag University, professor
CONTACT
Acinetobacter baumannii (A. baumannii) is Gram- negative, aerobic, glucose non-fermentative, non-motile coccobacillus, ubiquitous in nature, and persistent in healthcare settings. It is regarded as a significant opportunistic human pathogen.
This bacterium become a growing problem in hospitals as a predominant multidrug-resistant (MDR) bacterium. Horizontal acquisition of resistance genes is the main factor involved in the emergence of MDR .
There are many mechanisms to confer resistance to different classes of antibiotics in A. baumannii, one of them is multidrug efflux pumps. These efflux pumps are important source of MDR, which export antibiotics from the cell, increasing their antibiotic resistance.
AdeABC is one of the most important efflux systems, belonging to the RND family in Acinetobacter, which plays an important role in the resistance to a broad group of antibiotics; its genes are chromosomal and encode three genes, i.e., AdeB, AdeA, and AdeC, forming an operon in the vicinity. In addition, the expression of AdeABC is done by a two-component system, which includes a response regulator (AdeR) and a sensor kinase (AdeS) .
The ability of Acinetobacter spp. to form biofilm that enables bacterial survival in hospital settings, especially in ICUs, is the most significant contributing factor to their virulence, and this trait is also responsible for their notable antibiotic resistance. Several biofilm-related genes influence antimicrobial susceptibility, suggesting an association between the biofilm-forming ability of Acinetobacter spp. and their antibiotic resistance patterns (MDR/XDR)
Zinc oxide nanoparticles (ZnO NPs) are one of the most important nanoparticles of metal oxides; it is a unique and inorganic materials that can be used in several biological applications (anti-bacterial, anti-inflammatory). ZnO NPs exhibit distinctive properties other than other nanoparticles such as higher solubility, better biofilm penetration and effective drug delivery . ZnO NPs have been reported to have antimicrobial properties such as disrupting the cell membrane of pathogens, accumulating in the cell and producing toxic H2O2 (hydrogen peroxide)
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Samples will be cultured on MacConkey agar. Morphological identifications of growth isolates by Gram staining, colony features and conventional biochemical tests. All isolates will be identified to species level using automated bacterial identification systems.
Strains confirmed as A. baumannii will be examined for their different antibiotic susceptibility by modified Kirby Bauer's disc diffusion method on Mueller Hinton Agar.
The biofilm formation activity of A. baumannii isolates will be tested using the microtitre plate technique
Detection of the effect of ZnO NPs on the biofilm producer MDR A. baumannii strains using the same method
Time frame: October 2024 to December 2025
A. baumannii antibiotic susceptibility profile will be done using modified kirbybeur method
Time frame: October 2024 to December 2025
Isolation and identification of A. baumannii from different clinical samples using MacConKey medium, oxidase test. TSI, And automated identification ViteK system
Time frame: October 2024 to December 2025
Detection of A. baumannii strains which produce biofilm using tissue culture plates and Gram stain
Time frame: October 2024 to December 2025
Assessment of ability of ZnO NPs to inhibit the phenomenon of biofilm formation by MDR A. baumannii strains using ZnO NPs to be applied by different concentrations on tissue culture plates and measure the degree of Biofilm formation using ELISA
Time frame: October 2024 to December 2025
Evaluation the effect of ZnO NPs on the expression of some efflux pump genes and biofilm related genes in MDR A. baumannii strains using real time PCR(Polymerase Chain reaction)
Contact information is provided by the study sponsor or research team.
Noha Saber Shafik, lecturer
CONTACT
Shimaa Anwar Ahmed, Assistant Lecturer
CONTACT
Sohag University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01089712
Cardiac Surgery, Cross Infection
Atlanta, Georgia, United States
View Trial DetailsNCT00502801
Bacterial Infections, Bacterial Infections and Mycoses
Palm Springs, California, United States
View Trial DetailsNCT00150332
Cross Infection, Disease Attributes
Kamogawa, Chiba, Japan
View Trial DetailsNCT04600752
Ear Diseases, Infections
Raipur, Chhattisgarh, India
View Trial Details